Results 131 to 140 of about 84,866 (261)

Cardiometabolic Treatment Gap in Routine Psychiatric Care: A Cross‐Sectional Study of 1553 Patients

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background People with severe mental illness (SMI) have elevated cardiometabolic morbidity and mortality, with similar concerns increasingly reported in other psychiatric conditions including anxiety disorders and ADHD. Somatic conditions are often underdiagnosed and pharmacologically undermanaged in this population.
Vincent Achour, Melanie Faugere, Laurent Boyer, Christophe Lançon, Theo Korchia   +4 more
wiley   +1 more source

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

ClinicoEconomics and Outcomes Research
Christopher Zacker,1 Justin T Puckett,2 Sachin Kamal-Bahl2 1Cerevel Therapeutics, LLC, Cambridge, MA, USA; 2COVIA Health Solutions, Ambler, PA, USACorrespondence: Sachin Kamal-Bahl, COVIA Health Solutions, 915 Brewster Lane Ambler, PA 19002, Tel +1 267 ...
Zacker C, Puckett JT, Kamal-Bahl S
doaj  

Caregivers' Preference for Antipsychotic Medication for Youth Less Than 18 Years-Old: A Discrete Choice Experiment Pilot. [PDF]

Patient Prefer Adherence
Fu YH, Bozzi LM, Butler B, dosReis S.
europepmc   +1 more source

Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA)
Hannah Buchbauer, Mazda Adli, Peter Schlattmann, Maximilian Berger, Tom Bschor, Thomas Stamm, Joachim Behr, Roland Ricken, Pichit Buspavanich   +8 more
wiley   +1 more source

Association of psychotropic medications with the use of coercive measures and recidivism during forensic psychiatric care: a Swedish nationwide register-based study. [PDF]

BMJ Ment Health
Sitter TM, Savinen S, Andiné P, Fernqvist A, Edberg H, Brikell I, D'Onofrio BM, Hirvikoski T, Kuja-Halkola R, Szwajda A, Fazel S, Nilsson T, Chang Z.   +12 more
europepmc   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Specific Cultural Myths Impacting Antipsychotic Drug Adherence: Reclaiming Healthy Thinking Through Emotional Recovery. [PDF]

Schizophr Bull Open
Ryan SM.
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Next-step treatment for schizophrenia non-responsive to antipsychotics: a systematic review and network meta-analysis. [PDF]

EClinicalMedicine
Furukawa Y, Salahuddin NH, Wei Y, Pinioti E, Kim DD, Milosavlijević F, Siafis S, Schneider-Thoma J, Samara M, Bighelli I, Leucht S.   +10 more
europepmc   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source